Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000094.xml
Z Gastroenterol 2021; 59(10): 1120-1121
DOI: 10.1055/a-1645-2549
DOI: 10.1055/a-1645-2549
Mitteilungen der DGVS
Stellungnahme zur Änderung der Arzneimittel-Richtlinie: Anlage VIIa (Biologika und Biosimilars) – Erstfassung
Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), des Kompetenznetzes Darmerkrankungen und des Berufsverbandes Niedergelassener Gastroenterologen Deutschlands (bng) vom 12. Juli 2021.
Publication History
Article published online:
12 October 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Høivik ML, Bernklev T, Solberg IC. et al IBSEN Study Group.Patients with Crohn’s disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study. J Crohns Colitis 2012; 6 (04) 441-453 DOI: 10.1016/j.crohns.2011.10.001. . Epub 2011 Nov 9.
- 2 Høivik ML, Moum B, Solberg IC. et al IBSEN Group. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut 2013; 62 (03) 368-375 DOI: 10.1136/gutjnl-2012-302311. . Epub 2012 Jun 20.
- 3 European Medicines Agency: Guideline on similar biological medicinal products. Oct 23, 2014 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC50017%6768.pdf
- 4 Jørgensen KK, Olsen IC, Goll GL. et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017; 389: 2304-2316 DOI: 10.1016/S0140- 6736(17)30068-5.